Ticagrelor Improves Endothelial Function by Decreasing Circulating Epidermal Growth Factor (EGF)

Ticagrelor is one of the most powerful P2Y(12) inhibitor. We have recently reported that, in patients with concomitant Stable Coronary Artery Disease (SCAD) and Chronic Obstructive Pulmonary Disease (COPD) undergoing percutaneous coronary intervention (PCI), treatment with ticagrelor, as compared to...

Descripción completa

Detalles Bibliográficos
Autores principales: Vieceli Dalla Sega, Francesco, Fortini, Francesca, Aquila, Giorgio, Pavasini, Rita, Biscaglia, Simone, Bernucci, Davide, Del Franco, Annamaria, Tonet, Elisabetta, Rizzo, Paola, Ferrari, Roberto, Campo, Gianluca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Physiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5900783/
https://www.ncbi.nlm.nih.gov/pubmed/29686623
http://dx.doi.org/10.3389/fphys.2018.00337

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5900783/
https://www.ncbi.nlm.nih.gov/pubmed/29686623
http://dx.doi.org/10.3389/fphys.2018.00337

Ejemplares similares